Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Obicetrapib on Lipoprotein Metabolism
NCT05972278Phase 1Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing Obicetrapib 10 mg with Placebo (2 arms). Primary endpoint: Fractional Catabolic Rate of apolipoprotein B100 in low-density lipoprotein. Started Dec 2023; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05972278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972278.